McNeil Expands Recall List

Article

The recall of children's OTC medication began in January with more than 500 lots of products being recalled, and the latest expansion of the recall includes 21 more lots.

McNeil Consumer Healthcare has expanded a recall of its OTC medications to include 21 additional lots. The company said in a news release that the lots were added to as a precautionary measure after a review determined that some packaging materials used in those lots had been shipped and stored on the same type of wooden pallet tied to the presence of 2,4,6-tribromoanisole in earlier recalled lots.

McNeil said it has stopped accepting shipments of materials from its suppliers on that type of pallet.

In January, the company recalled more than 500 lots of its OTC products—including Benadryl, Rolaids, and multiple variations of Motrin, Children's Motrin, Tylenol, and Children's Tylenol—following consumer complaints of moldy, musty or mildew-like odor.

The smell was linked to trace amounts of a chemical called 2,4,6-tribromoanisole, a degradant of 2,4,6-tribromophenol, which is a pesticide and flame retardant used to treat wooden pallets.

McNeil expanded the recall in June to include products it said were inadvertently omitted from the initial action.

For a complete list of the 21 lots in the current recall, click here.

Consumers who purchased products from the recalled lots should stop using the products and contact McNeil for instructions on receiving a refund or replacement, the manufacturer said. Adverse reactions to the products may be reported to the FDA’s MedWatch Program.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
A panel of 5 experts on iron deficiency anemia
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Phase 2 Data Shows KP1077 Meaningfully Improves Idiopathic Hypersomnia Symptoms
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
© 2024 MJH Life Sciences

All rights reserved.